Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:1.6.3.1 (NADPH oxidase)
 11,281 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Administration of nafenopin, diphenylhydantoin, phenobarbitone or the acetylenes BRL 15268 and BRL 19001 in the diet or, in the case of phenobarbitone, in drinking water reduced the body-lipid content of genetically-obese (ob/ob) mice. These compounds also reduced food intake in ob/ob mice. However, dietary restriction had less effect on body-lipid content than did the compounds. Nafenopin, diphenylhydantoin and BRL 15268 reduced the body-lipid content of normal mice and had no effect on food intake. Each of the compounds that reduced body-lipid content increased the liver weight of normal and ob/ob mice. BRL 15268 and BRL 19001 increased the maximum activity of NADPH oxidase in liver. It is proposed that these reductions in body-lipid content result from the increased metabolic rate involved in enlarging the liver and maintaining its increased size.
 ...
PMID:Effects of nafenopin, diphenylhydantoin, phenobarbitone and some acetylenes on body composition: is there a relationship between decreased carcass lipid and increased liver size and induction of drug metabolizing enzymes? 739 Jun 96